ACADEMIA
Yervoy Extends Survival of Terminal Melanoma Patients, Same Might Hold True for Other Immunotherapies: Prof.
Some 20-30% of patients with terminal malignant melanoma lived for 10 years after they took Bristol-Myers Squibb’s cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor Yervoy (ipilimumab), offering hope to patients who have had limited treatment options, a researcher says. Hiroyoshi Nishikawa,…
To read the full story
ACADEMIA
- Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- 5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





